Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia

Annals of the American Thoracic Society

Volumn 12, Issue 2, 2015, Pages 153-160

  Prina, Elena ^a,b   Ranzani, Otavio T ^a,b   Polverino, Eva ^a,c   Cillóniz, Catia ^a,c   Ferrer, Miquel ^a,c   Fernandez, Laia ^a,c   De La Bellacasa, Jorge Puig ^d   Menéndez, Rosario ^c,e   Mensa, Josep ^d   Torres, Antoni ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antibiotic therapy; Community acquired pneumonia; Infection

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; OXACILLIN; PENICILLIN DERIVATIVE; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HUMAN; IMMUNOCOMPROMISED PATIENT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; NURSING HOME; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SEX DIFFERENCE; SHOCK; ACUTE KIDNEY INJURY; AGE; BRONCHIECTASIS; COHORT ANALYSIS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; CONSCIOUSNESS DISORDERS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEVER; IMMUNOCOMPETENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PENICILLIN RESISTANCE; PHYSIOLOGY; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY, CHRONIC; STAPHYLOCOCCAL INFECTIONS; VERY ELDERLY;

ACUTE KIDNEY INJURY; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BETA-LACTAM RESISTANCE; BRONCHIECTASIS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; CONSCIOUSNESS DISORDERS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; FEVER; HUMANS; IMMUNOCOMPETENCE; MALE; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEX FACTORS; STAPHYLOCOCCAL INFECTIONS;

EID: 84926506282     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201407-305OC     Document Type: Article

References (30)

1. Viasus D, Garcia-Vidal C, Carratalà J. Advances in antibiotic therapy for community-acquired pneumonia. Curr Opin Pulm Med 2013;19:209-215.
2. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J, Jr.; Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155-164.
3. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
4. Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010;10:279-287.
5. Polverino E, Torres A, Menendez R, Cillóniz C, Valles JM, Capelastegui A, Marcos MA, Alfageme I, Zalacain R, Almirall J, et al.; HCAP Study investigators. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. Thorax 2013;68:1007-1014.
6. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008;197:1079-1081.
7. Sandiumenge A, Lisboa T, Gomez F, Hernandez P, Canadell L, Rello J. Effect of antibiotic diversity on ventilator-associated pneumonia caused by ESKAPE organisms. Chest 2011;140:643-651.
8. Sandiumenge A, Rello J. Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management. Curr Opin Pulm Med 2012;18:187-193.
9. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
10. Menéndez R, Torres A, Aspa J, Capelastegui A, Prat C, Rodríguez de Castro F; Sociedad Española de Neumología y Cirugía Torácica. Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR) [article in Spanish]. Arch Bronconeumol 2010;46:543-558
11. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S121.
12. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.
13. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 1989.
14. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer; 2009.
15. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849-1858.
16. Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, Tarsia P, Mantero M, Blasi F. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012;54:470-478.
17. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013;188:985-995.
18. Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, Micek ST, Kollef MH. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012;54:193-198.
19. Ewig S, Torres A. Healthcare-associated pneumonia: meeting the yeti. Eur Respir J 2011;38:755-757.
20. Ewig S, Welte T, Torres A. Is healthcare-associated pneumonia a distinct entity needing specific therapy? Curr Opin Infect Dis 2012;25:166-175.
21. Wunderink RG. Community-acquired pneumonia versus healthcareassociated pneumonia: the returning pendulum. Am J Respir Crit Care Med 2013;188:896-898.
22. Woodhead M. Pneumonia classification and healthcare-associated pneumonia: a new avenue or just a cul-de-sac? Thorax 2013;68:985-986.
23. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, et al.; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011;17(suppl 6):E1-E59.
24. Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, Pesci A, Blasi F, Torres A. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax 2013;68:997-999.
25. Kothe H, Dalhoff K. Pneumonia in the immunocompromised patient: respiratory emergencies. Leeds, UK: European Respiratory Society Journals Ltd; 2006. pp. 200-213.
26. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008;46:1121-1122, author reply 1122.
27. Maruyama T, Fujisawa T, Okuno M, Toyoshima H, Tsutsui K, Maeda H, Yuda H, Yoshida M, Kobayashi H, Taguchi O, et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis 2013;57:1373-1383.
28. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr., Musher DM, Niederman MS, et al.; Infectious Diseases Society of America, American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(suppl 2):S27-S72.
29. Torres A, Menéndez R. Enterobacteriaceae and Pseudomonas aeruginosa in community-acquired pneumonia: the reality after a decade of uncertainty? Eur Respir J 2010;35:473-474.
30. Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis 2013;13:268.